Drug Profile
Doxorubicin liposomal - Taiwan Liposome Company
Alternative Names: Doxolipad; Lipo-Dox; TLC 177Latest Information Update: 31 Oct 2022
Price :
$50
*
At a glance
- Originator Taiwan Liposome Company
- Developer Chang Gung Memorial Hospital; Taiwan Liposome Company; TTY Biopharm
- Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
- Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; Kaposi's sarcoma; Ovarian cancer
- Phase II HER2 negative breast cancer
Most Recent Events
- 09 Sep 2022 Initial efficacy and adverse events data from a phase II trial in Breast cancer presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)
- 11 Mar 2021 No development reported - Phase-III for Ovarian cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan, India (IV)
- 29 May 2019 The Committee for Medicinal Products for Human Use (CHMP) confirms the adoption of negative opinion for MAA after re-examination for doxorubicin liposomal for Breast cancer and Ovarian cancer